Vera Therapeutics, Inc. (VERA): Capital Expenditures
$630.0K
Year ended 2025-12-31
$258.0K
Trailing 12 months to 2026-06-30
+116.6%
3-year compound annual growth
+44.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $630.0K | -35.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $972.0K | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $63.0K | +1.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $62.0K | n/a | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $0 | -100.0% | 2023-03-28, From 2021-01-01 |
| 2020-12-31 | $99.0K | n/a | 2022-03-28, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $630.0K | -35.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $6.64M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $657.0K | +372.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $2.35M | +90.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.57M | +466.1% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
Compare VERA, KURA, SDGR, SMMT side by side · Screen every company in Pharmaceutical Preparations ↗